Innovate Biopharmaceuticals, Inc. (INNT) EPS Estimated At $-0.20

August 12, 2018 - By Mark Mitchell

Analysts expect Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) to report $-0.20 EPS on August, 20.They anticipate $1.70 EPS change or 89.47 % from last quarter’s $-1.9 EPS. After having $-0.76 EPS previously, Innovate Biopharmaceuticals, Inc.’s analysts see -73.68 % EPS growth. The stock decreased 10.25% or $0.62 during the last trading session, reaching $5.43. About 837,292 shares traded or 57.90% up from the average. Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) has risen 156.72% since August 13, 2017 and is uptrending. It has outperformed by 144.15% the S&P500.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. The company has market cap of $139.53 million. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH). It currently has negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

More notable recent Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) news were published by: which released: “85 Biggest Movers From Yesterday” on August 09, 2018, also with their article: “Pre-Open Movers 07/17: (AST) (INNT) (CDMO) Higher; (AVEO) (NFLX) (EOLS) Lower (more…)” published on July 17, 2018, published: “Why Blue Apron, Tribune Media, and Innovate Biopharmaceuticals Slumped Today” on July 16, 2018. More interesting news about Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) were released by: and their article: “Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New …” published on August 03, 2018 as well as‘s news article titled: “Why Innovate Biopharmaceuticals Stock Cratered Today” with publication date: July 16, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.